3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
275
Carcinoma, Non-Small-Cell Lung
226
Prostatic Neoplasms
182
Neoplasms
174
Multiple Myeloma
138
Lung Neoplasms
137
Neoplasm Metastasis
102
Colorectal Neoplasms
101
Melanoma
87
Ovarian Neoplasms
80
Pancreatic Neoplasms
74
Leukemia, Myeloid, Acute
74
Lymphoma
69
Carcinoma, Renal Cell
65
Leukemia, Lymphocytic, Chronic, B-Cell
64
Brain Neoplasms
63
Lymphoma, Non-Hodgkin
62
Squamous Cell Carcinoma of Head and Neck
61
Urinary Bladder Neoplasms
57
Recurrence
56
Hematologic Neoplasms
56
Carcinoma, Hepatocellular
54
Head and Neck Neoplasms
53
Triple Negative Breast Neoplasms
52
Glioblastoma
49
Lymphoma, Follicular
48
Endometrial Neoplasms
47
Uterine Cervical Neoplasms
46
Precursor Cell Lymphoblastic Leukemia-Lymphoma
45
Stomach Neoplasms
44
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Biochemically Recurrent Prostate Cancer
×
90 days
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled